Vitae Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing novel and small molecule drugs for diseases with unmet medical needs in the United States. Its products include VTP-43742 in Phase I clinical trial for the treatment of autoimmune disorders, including psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, and multiple sclerosis; VTP-38543 in Phase IIa for the treatment of atopic dermatitis; and BI 1147560 for the treatment and prevention of Alzheimer's disease. The company’s products also include VTP-34072 that is in Phase II clinical trial for the treatment of type 2 diabetes; and VTP-38443 for the treatment of acute coronary syndrome. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania. Vitae Pharmaceuticals, Inc. operates as a subsidiary of AbbVie Inc.